Key issues in the diagnosis and treatment of multiple sclerosis: An overview

Neurology

Volumn 59, Issue 6 SUPPL. 3, 2002, Pages

  O'Connor, Paul ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NEUTRALIZING ANTIBODY; PARACETAMOL; STEROID;

ALOPECIA; AMENORRHEA; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC APPROACH ROUTE; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEVER; GEOGRAPHIC DISTRIBUTION; HUMAN; INFLUENZA; INJECTION SITE; LEUKOPENIA; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATHOGENESIS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; RISK FACTOR; SWEATING; SYMPTOMATOLOGY; URINARY TRACT INFECTION;

EID: 0037167566     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.59.6_suppl_3.s1     Document Type: Review

References (161)

1. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
2. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146.
3. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281-300.
4. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998;121:495-503.
5. Sailer M, O'Riordan JI, Thompson AJ, et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 1999;52:599-606.
6. Brex P, Ciccarelli O, O'Riordan J, Sailer M, Thompson A, Miller D. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346: 158-164.
7. Paty DW, Ebers GC. Clinical features. In: Paty DW, Ebers GC, eds. Multiple sclerosis. Philadelphia: FA Davis, 1997: 135-191.
8. Vukusic S, Confavreux C. The natural history of multiple sclerosis. In: Cook SD, ed. Handbook of multiple sclerosis. 3rd ed. New York: Marcel Dekker, 2001:433-447.
9. Paty DW, Noseworthy JH, Ebers GC. Diagnosis of multiple sclerosis. In: Paty DW, Ebers GC, eds. Multiple sclerosis. Philadelphia: FA Davis, 1997:48-134.
10. Miller AE. Clinical features. In: Cook SD, ed. Handbook of multiple sclerosis. 3rd ed. New York: Marcel Dekker, 2001: 231-232.
11. Ebers GC, Sadovnick AD. Epidemiology. In: Paty DW, Ebers GC, eds. Multiple sclerosis. Philadelphia: FA Davis, 1997:5-28.
12. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
13. Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999;122:1941-1950.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
15. McAlpine D. The benign form of multiple sclerosis. A study based on 241 cases seen within 3 years of onset and followed up until the 10th year or more of the disease. Brain 1961;84: 186-203.
16. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987;14:255-261.
17. Ebers GC, Paty DW. Natural history studies and applications to clinical trials. In: Paty DW, Ebers GC, eds. Multiple sclerosis. Philadelphia: FA Davis, 1997:192-228.
18. Confavreux C, Grimaud J, Vukusic S, Moreau T. Peut-on predire l'evolution de la sclerose en plaques? Rev Neurol 1998;154:624-628.
19. Weinshenker BG, Rice GPA, Noseworthy JH, Carniere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. IV. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991;114:1057-1067.
20. Bronnum-Hansen H. Survival in disseminated sclerosis in Denmark. A nation-wide study of the period 1948-1986. Ugeskr Laeger 1995;157:7131-7135.
21. Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-994.
22. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991;41:1193-1196.
23. Kantarci OH, Weinshenker BG. Prognostic factors in multiple sclerosis. In: Cook SD, ed. Handbook of multiple sclerosis. 3rd ed. New York: Marcel Dekker, 2001:449-463.
24. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course. Brain 1989;112:1419-1428.
25. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438.
26. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993;116: 135-146.
27. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635-641.
28. Sweeney VP, Sadovnick AD, Brandejs V. Prevalence of multiple sclerosis in British Columbia. Can J Neurol Sci 1986;13: 47-51.
29. Hader WJ. Prevalence of multiple sclerosis in Saskatoon. Can Med Assoc J 1982;127:295-297.
30. Hader WJ, Elliot M, Ebers GC. Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada. Neurology 1985;38:617-621.
31. Pryse-Phillips W. The incidence and prevalence of multiple sclerosis in Newfoundland and Labrador, 1960-1984. Ann Neurol 1986;20:323-328.
32. Kurtzke JF. A reassessment of the distribution of multiple sclerosis: parts I and II. Acta Neurol Scand 1975;51:110-157.
33. Pryse-Phillips W, Costello F. The epidemiology of multiple sclerosis. In: Cook SD, ed. Handbook of multiple sclerosis. 3rd ed. New York: Marcel Dekker, 2001:15-31.
34. Hammond SR, McLeod JG, Millingen KS, et al. The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart. Brain 1988;111:1-25.
35. Kuroiwa Y, Shibasaki H, Ikeda M. Prevalence of multiple sclerosis and its north-south gradient in Japan. Neuroepidemiology 1983;2:62-69.
36. Kurtzke JF, Beebe GW, Norman JE. Epidemiology of multiple sclerosis in U.S. veterans. I. Race, sex and geographic distribution. Neurology 1979;29:1228-1235.
37. Skegg DC, Corwin PA, Craven RS, Malloch JA, Pollock M. Occurrence of multiple sclerosis in the north and south of New Zealand. J Neurol Neurosurg Psychiatry 1987;50:134-139.
38. Dean G. Annual incidence, prevalence and mortality of MS in white South African-born and in white immigrants to South Africa. BMJ 1967;2:724-730.
39. Gale CR. Migrant studies in multiple sclerosis. Prog Neurobiol 1995;47:425-448.
40. Sheremata WA, Poskanzer DC, Withum DG, MacLeod CL, Whiteside ME. Unusual occurrence on a tropical island of multiple sclerosis. Lancet 1985;2:618. Letter.
41. Irvine DG, Schiefer HB. Geotoxicology of multiple sclerosis: the Henribourg, Saskatchewan, cluster focus. II. The soil. Sci Total Environ 1988;77:175-188.
42. Murray TJ. An unusual occurrence of multiple sclerosis in a small rural community. Can J Neurol Sci 1976;3:163-166.
43. Kinnunen E. Multiple sclerosis in Finland: evidence of increasing frequency and uneven geographic distribution. Neurology 1984;34:457-461.
44. Poskanzer DC, Walker AM, Prenney LB, Sheridan JL. The etiology of multiple sclerosis: temporal-spatial clustering indicating two environmental exposures before onset. Neurology 1981;31:708-713.
45. Warren S, Warren KG. Prevalence, incidence and characteristics of multiple sclerosis in Westlock County, Alberta, Canada. Neurology 1993;439:1760-1763.
46. Hammond SR, English DR, McLeod JG. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 2000;123:968-974.
47. Yu YL, Woo E, Hawkins BR, Ho HC, Huang CY. Multiple sclerosis amongst Chinese in Hong Kong. Brain 1989;112: 1445-1467.
48. Gronning M, Mellgren SI. Multiple sclerosis in the two northernmost counties of Norway. Acta Neurol Scand 1985; 72:321-327.
49. Ebers GC. Genetic factors in multiple sclerosis. Neurol Clin 1983;1:645-654.
50. Hader WJ, Feasby TE, Noseworthy JH, Rice GP, Ebers GC. Multiple sclerosis in Canadian Native people. Neurology 1985;35:300. Abstract.
51. Yaquib BA, Daif AK. Multiple sclerosis in Saudi Arabia. Neurology 1988;38:621-623.
52. Vassallo L, Elian M, Dean G. Multiple sclerosis in southern Europe. II. Prevalence in Malta in 1978. J Epidemiol Comm Health 1979;33:111-113.
53. Dean G, Grimaldi G, Kelly R, Karheusen L. Multiple sclerosis in southern Europe. I. Prevalence in Sicily in 1975. J Epidemiol Comm Health 1979;33:107-110.
54. Wynn DR, Kurland LT, O'Fallon WM, Rodriguez M. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 1990;40:780-786.
55. Granieri E, Casetta I, Tola MR. Multiple sclerosis: does epidemiology contribute to providing etiological clues? J Neurol Sci 1993;115(Suppl):16-23.
56. McLeod JG, Hammond SR, Hallpike JF. Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results. Med J Aust 1994;1603:117-122.
57. Sadovnick AD, Baird PA. The familial nature of multiple sclerosis: age-corrected empiric recurrence risks of children and siblings of patients. Neurology 1988;38:990-991.
58. Sadovnick AD, Baird PA, Ward RH. Multiple sclerosis: update risks for relatives. Am J Med Genet 1988;29:533-541.
59. Ebers GC, Sadovnick AD. Susceptibility: genetics in multiple sclerosis. In: Cook SD, ed. Multiple sclerosis. 3rd ed. New York: Marcel Dekker, 1997:29-47.
60. Sadovnick AD, Armstrong H, Rice GPA, et al. A population-based twin study of multiple sclerosis: update. Ann Neurol 1993;33:282-285.
61. Kinnunen E, Juntunen J, Ketonen L, et al. Genetic susceptibility to multiple sclerosis: a co-twin study of a nation-wide series. Arch Neurol 1988;45:1108-1111.
62. Bobowick AR, Kurtzke JF, Brody JA, Hrubec Z, Gillespie M. Twin study of multiple sclerosis: an epidemiologic inquiry. Neurology 1978;28:978-987.
63. Heltberg A, Holm NV. Concordance in twins and recurrence in sibships in multiple sclerosis. Lancet 1982;1:1068. Letter.
64. Mumford CJ, Wood NW, Kellar-Wood H, Thorpe J, Miller D, Compston DAS. The British Isles survey of multiple sclerosis in twins. Neurology 1994;44:11-15.
65. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis susceptibility: a critical review. Nature 1995;377:150-151.
66. Sadovnick AD, Ebers GC, Dyment D, Risch NJ, Canadian Collaborative Study Group. Evidence for the genetic basis of multiple sclerosis. Lancet 1996;347:1728-1730.
67. Hillert J, Masterman T. The genetics of multiple sclerosis. In: Cook SD, ed. Handbook of multiple sclerosis. 3rd ed. New York: Marcel Dekker, 2001:33-65.
68. Hillert J, Olerup O. Germ-line polymorphism of TCR genes and disease susceptibility-fact or hypothesis? Immunol Today 1992;13:47-49.
69. Hillert J. Immunoglobulin gamma constant gene region polymorphisms in multiple sclerosis. J Neuroimmunol 1993;43: 9-14.
70. Hashimoto LL, Walter MA, Cox DW, Ebers GC. Immunoglobulin heavy chain variable region polymorphisms and multiple sclerosis susceptibility. J Neuroimmunol 1993;44: 77-83.
71. Fugger LM, Morling N, Sandberg-Wollheim M, Ryder LP, Svejgaard A. Tumour necrosis factor alpha gene polymorphism in multiple sclerosis and optic neuritis. J Neuroimmunol 1990;27:85-88.
72. Rose J, Gerken S, Lynch S, et al. Genetic susceptibility in familial multiple sclerosis not linked to the myelin basic protein gene. Lancet 1993;341:1179-1181.
73. Tienari PJ, Wikstrom J, Sajantila A, Palo J, Peltonen L. Genetic susceptibility to multiple sclerosis linked to myelin basic protein gene. Lancet 1992;340:987-991.
74. Ligers A, Xu C, Saarinen S, Hillert J, Olerup O. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol 1999;97:182-190.
75. Flinstad Harbo H, Celius EG, Vartdal F, Spurkland A. CTLA-4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens 1999;53:106-110.
76. Kuokkanen S, Gschwend M, Rioux JD, et al. Genomewide scan of multiple sclerosis in Finnish multiplex families. Am J Hum Genet 1997;61:1379-1387.
77. Sawcer SJ, Jones HB, Feakes R, et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nature Genet 1996;13:464-468.
78. Haines JL, Ter-Minassian M, Bazyk A, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex: the Multiple Sclerosis Genetics Group. Nature Genet 1996;13:469-471.
79. Ebers GC, Kukay K, Bulman DE, et al. A full genome search in multiple sclerosis. Nature Genet 1996;13:472-476.
80. Lauer K. Diet and multiple sclerosis. Neurology 1997; 492(Suppl 2):S55-61.
81. Butler EJ. Chronic neurological disease as a possible form of lead poisoning. J Neurol Neurosurg Psychiatry 1952;15:119-128.
82. Mortensen JT, Bronnum-Hansen H, Rasmussen K. Multiple sclerosis and organic solvents. Epidemiology 1998;92:168-171.
83. McGrother CW, Dugmore C, Phillips MJ, Raymond NT, Garrick P, Baird WO. Multiple sclerosis, dental caries and fillings: a case-control study. Br Dent J 1999;1875:261-264.
84. Goodin DS, Ebers GC, Johnson KP, Rodriguez M, Sibley WA, Wolinsky JS. The relationship of MS to physical trauma and psychological stress. Neurology 1999;52:1737-1745.
85. Matthews WB. Some aspects of the natural history. In: Matthews WB, Acheson ED, Batchelor JR, Weller RO, eds. McAlpine's multiple sclerosis. New York: Churchill Livingstone, 1985:73-95.
86. Freedman D, Dosemeci M, Alavanja M. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup Environ Med 2000;57:418-421.
87. Hayes CE, Cantorna MT, DeLuca HF. Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med 1997;216:21-27.
88. Cook SD, Rohowsky-Kochan C, Bansil S, Dowling PC. Evidence for multiple sclerosis as an infectious disease. Acta Neurol Scand 1995;161(Suppl):34-42.
89. Dal Canto MC. Experimental models of virus-induced demyelination. In: Cook SD, ed. Handbook of multiple sclerosis. 3rd ed. New York: Marcel Dekker, 2001:67-113.
90. Telenti A, Aksamit AJ, Proper J, Smith TE. Detection of JC virus DNA by polymerase chain reaction in patients with progressive multifocal leukoencephalopathy. J Infect Dis 1990;162:858-861.
91. Petito CK, Navia BA, Cho ES, Jordan BD, George DC, Price RW. Vacuolar myelopathy pathologically resembling sub-acute combined degeneration in patients with the acquired immunodeficiency syndrome. N Engl J Med 1985;312:874-879.
92. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2:407-410.
93. Dyken PR, Cunningham SC, Ward LC. Changing character of subacute sclerosing panencephalitis in the United States. Pediatr Neurol 1989;5:339-341.
94. Kastrukoff LF, Rice GPA. Virology. In: Paty DW, Ebers GC, eds. Multiple sclerosis. Philadelphia: FA Davis, 1997:370-402.
95. Moore GRW. Neuropathology and pathophysiology of the multiple sclerosis lesion. In: Paty DW, Ebers GC, eds. Multiple sclerosis. Philadelphia: FA Davis, 1997:257-327.
96. Prineas JW. Pathology of multiple sclerosis. In: Cook SD, ed. Handbook of multiple sclerosis. 3rd ed. New York: Marcel Dekker, 2001:289-324.
97. Raine CS. Demyelinating diseases. In: Davis RL, Robertson DM, eds. Textbook of neuropathology. 2nd ed. Baltimore: Williams & Wilkins, 1991:535-620.
98. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999;122:2279-2295.
99. Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H. Multiple sclerosis: lessons from neuropathology. Semin Neurol 1998;18:337-349.
100. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
101. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120: 393-399.
102. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70.
103. Arnold DL. Magnetic resonance spectroscopy: imaging axonal damage in MS. J Neuroimmunol 1999;98:2-6.
104. Whitaker JN, Mitchell GW. A possible role for altered myelin basic protein in multiple sclerosis. Ann Neurol 1996;40:3-4.
105. Zang Y, Kozovska M, Hong J, et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur J Immunol 1999;29:1692-1700.
106. Zipp F, Otzelberger K, Dichgans J, Martin R, Weller M. Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis. J Neuroimmunol 1998;86:151-154.
107. Dowling PC, Shang G, Raval S, Menonna J, Cook SD, Husar W. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 1996;184: 1513-1518.
108. D'Souza SD, Bonetti B, Balasingam V, et al. Multiple sclerosis: Fas signalling in oligodendrocyte cell death. J Exp Med 1996;184:2361-2370.
109. Tuohy VK, Yu M, Yin L, et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1998;164:93-100.
110. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999;12:295-302.
111. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
112. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-2069.
113. Fazekas F, Offenbacher H, Fuchs S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988;38:1822-1825.
114. Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:180-185.
115. Tintore M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 2000;21:702-706.
116. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582.
117. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
118. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000;47:831-835.
119. Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis. Clin Neurol Neurosurg 2001;103:1-11.
120. Sackett D. Rules of evidence and clinical recommendations. Can J Cardiol 1993;9:487-489.
121. Goodin D, Frohman E, Garmany G, et al. Disease-modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:168-178.
122. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
123. IFNB Multiple Sclerosis Study Group, and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
124. Jacobs L, Cookfair D, Rudick R, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
125. Jacobs L, Munschauer F. Treatment of multiple sclerosis with interferons. In: Rudick R, Goodkin D, eds. Treatment of multiple sclerosis: trial design, results and future perspectives. London: Springer, 1992:223-250.
126. US Food and Drug Administration. Summary basis for approval of Avonex® (95-0979 95-0975; 1995; Cambridge MA, Data on file at FDA).
127. Rudick R, Goodkin D, Jacobs L, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-363.
128. Simon J, Campion LJ, Wende K, et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol 1998;43:79-87.
129. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
130. Lui C, Li Wan Po A, Blumhardt L. Summary measure statistic for assessing outcome of treatment trials in relapsing and remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:726-729.
131. PRISMS Study Group, and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001;56:1628- 1636.
132. Johnson K, Brooks B, Cohen J, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double- blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
133. Copaxone prescribing information. Available at: www.copaxone.com/pi/copaxonepi.pdf Rev. R 5/2000.
134. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6:255-266.
135. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997;349:589-593.
136. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118.
137. Edan G, Brochet B, Brassat D, et al. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients. Neurology 2002;58(Suppl 3):A168. Abstract.
138. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-159.
139. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
140. Betaseron prescribing information. In: Compendium of pharmaceuticals and specialities. Ottawa: Canadian Pharmacist Association 2002:226-230.
141. Goodkin D, and the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 2000;54:2352. Abstract.
142. Secondary Progressive Efficacy Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Neurology 2001;56:1496-1504.
143. Li D, Zhao G, Paty D, University of British Columbia MS/ MRI Analysis Research Group, and the SPECTRIMS Study Group. Randomized controlled trial of interferon beta-1a in secondary progressive MS. MRI results. Neurology 2001;56: 1505-1518.
144. Hartung H-P, Gonsette R, and the MIMS-Study Group. Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind European Phase III multicenter study-clinical results. Mult Scler 1998;4:325. Abstract.
145. Novantrone and multiple sclerosis. Available at: www.immunex.com/cgi-bin/medinfo/pdf/nov322100.pdf. Accessed May 20, 2002.
146. Hartung H-P, Gonsette R, and the MIMS Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomized, observer-blind phase III trial: clinical results and three-year follow-up. Neurology 1999; 53(Suppl 2):A280. Abstract.
147. Hartung H-P, Gonsette R, and the MIMS Study Group. Mitoxantrone in progressive multiple sclerosis (MS): clinical results and three-year follow-up of the MIMS trial. Mult Scler 1999;5(Suppl 1):S15. Abstract.
148. Cohen J, Goodman A, Heidenreich F, et al. Results of IMPACT, a phase 3 trial of interferon beta-1a in secondary progressive multiple sclerosis. Neurology 2001;56(Suppl): A148. Abstract.
149. Fischer J, Rudick R, Cutter G, Reingold S. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244-250.
150. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-1460.
151. Coyle P. Results of comparative efficacy trial using two formulations of interferon beta-1a in RRMS. J Neurol Sci 2001; 187(Suppl 1):S436. Abstract.
152. Färkkila M, and the EVIDENCE Study Group. The EVIDENCE Study: direct comparative study of IFN beta-1a three times weekly (Rebif®) and once weekly (Avonex®) in RRMS. Mult Scler 2001;7(Suppl 1):S94.
153. Panitch H, Coyle P, Francis G, et al. The evidence of interferon dose response: European-North American Comparative Efficacy (EVIDENCE) Study: 48-week data. Neurology 2002;58(Suppl 3):A86. Abstract.
154. Comparative study of Rebif to Avonex and orphan exclusivity. Available at: www.fda.gov/cber/review/ifnbser030702rl. pdf. Accessed May 20, 2002.
155. Paty DW. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can J Neurol Sci 1988; 15:266-272.
156. Barkhof F, Scheltens P, Frequin S, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging versus clinical findings in determining disease activity. AJR 1992;159:1041-1047.
157. Prentice R. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-440.
158. Paty D, Li D, UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a controlled multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 662-667.
159. Li D, Paty D, UBC MS/MRI Analysis Research Group, and the PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46:197-206.
160. Comi G, Filippi M, Wolinsky JS, and the European/Canadian Glatiramer Acetate Study Group. European/Canadian multi-center, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297.
161. Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology 2001;57:731-733.